SSG
PCRX icon

Summit Securities Group’s Pacira BioSciences PCRX Stock Holding History

Summit Securities Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
+936
New +$22.1K ﹤0.01% 688
2014
Q1 		– Sell
-60
Closed -$3K – 537
2013
Q4 		$3K Buy
+60
New +$3.15K ﹤0.01% 420

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Securities Group's PCRX Position: Q2 2026 in Review

Summit Securities Group opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 936 shares worth $23.7K. The stake represents ﹤0.01% of the portfolio and ranks #688 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in PCRX as recently as Q4 2013.

Summit Securities Group first reported a position in PCRX in Q4 2013 and has held it in 2 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Summit Securities Group held 936 shares of Pacira BioSciences worth $23.7K as of Q2 2026.
  • Pacira BioSciences was a new Summit Securities Group position in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #688 holding.
  • Summit Securities Group first reported a position in Pacira BioSciences in Q4 2013 and has held it in 2 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.